BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn

Nearly two years after the FDA poured cold water on a potential regulatory bid for BrainStorm Cell Therapeutics’ NurOwn, the investigational ALS therapy will get a public hearing.